The CELMoD Paradigm: Redefining Early Relapse Multiple Myeloma

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, explain how mezigdomide’s complete cereblon E3 ligase engagement overcomes IMiD resistance in heavily pretreated multiple myeloma.

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, discuss the immunologic and mechanistic synergy between CELMoDs and standard myeloma backbone therapies.

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, discuss how sparing patients from IMiD-related GI toxicity and neutropenic infections with CELMoDs may extend treatment duration and progression-free survival.

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, discuss using CELMoDs to debulk tumor or restore T-cell fitness between T-cell–redirecting therapies in relapsed/refractory multiple myeloma.

Paul G. Richardson, MD; and Muhamed Baljevic, MD, FACP, discussed the mechanism, synergy, tolerability, and sequencing of CELMoDs in multiple myeloma.